Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Pharmacies told to stop making custom versions of Wegovy and Zepbound after shortages declared officially over ...

Shares of Novo Nordisk, the Danish pharmaceutical company ... line disruptions pushing physicians to prescribe Eli Lilly's tirzepatide-based injection drugs Zepbound and Mounjaro instead.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.